Responses to TKIs are short-lived in the advanced phases of CML due to drug resistance and relapses driven by both BCR::ABL1 kinase-dependent and -independent mechanisms [6]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.